about
Interferon-λ: Immune Functions at Barrier Surfaces and BeyondIFN-λ: A New Inducer of Local Immunity against Cancer and InfectionsInterferon-Lambda: A Potent Regulator of Intestinal Viral Infections.Granzyme M has a critical role in providing innate immune protection in ulcerative colitisIFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infectionAnti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C.Type III Interferons in Hepatitis C Virus Infection.Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth.Natural Killer Cell Assessment in Peripheral Circulation and Bronchoalveolar Lavage Fluid of Patients with Severe Sepsis: A Case Control StudyInvolvement of NK Cells in IL-28B-Mediated Immunity against Influenza Virus Infection.In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.Targeting IFN-λ: therapeutic implications.Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.IFN-λ cancer immunotherapy: new kid on the block.Contribution of type III interferons to antiviral immunity: location, location, location.Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology.IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function.Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.Defective natural killer cell activity in a mouse model of eczema herpeticum.Interleukin-28B dampens airway inflammation through up-regulation of natural killer cell-derived IFN-γ.Interferon-λs: Front-Line Guardians of Immunity and Homeostasis in the Respiratory Tract.IFN type III: in vivo NK cell response.Interferon-γ-Mediated Natural Killer Cell Activation by an Aqueous Panax ginseng Extract.Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-λ2 or IL-29/IFN-λ1.Interferon Lambda Genetics and Biology in Regulation of Viral Control.Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs.Identification of a Predominantly Interferon-λ-Induced Transcriptional Profile in Murine Intestinal Epithelial Cells.Interferon lambda is required for interferon gamma-expressing NK cell responses but does not afford antiviral protection during acute and persistent murine cytomegalovirus infection.
P2860
Q26801049-98C389DF-EFDC-4581-B9E2-22BAE2589DD5Q28072995-4B15616A-B33B-4C19-A1D9-72136A621BDFQ33854465-68E9FD23-9FD9-4600-A693-6C00E2C3C3AAQ37151517-5B05E4F2-E763-4C7F-9A75-349A5C0BD19AQ37216063-29D7F384-67AF-4C6F-A630-66BC89A6EA3CQ37222143-DF24F9C9-6529-4D56-BE67-D844CA7570DFQ37226696-BDD30444-6B40-4159-AC4D-57FFDCD049A0Q37528605-85375A12-CFFD-441E-A125-26B22E26912BQ37580211-CD2536AF-EE81-4364-AC4B-4B34FCE1988AQ37729270-6F554260-051E-4A60-804C-5BE7AE1D3BD7Q38668279-DA0620EC-92DE-4A84-94AB-1B94F224E35FQ38677593-58D55408-26AA-42D8-A91D-D82C110D36E7Q38733510-43725D34-834E-4D3E-83AB-0E1A89E8348BQ38816811-51587534-2755-405B-93A5-40D0057C8043Q38875021-DEDBC16A-2C8C-4D9B-96A8-8F876B473165Q38887297-82918C58-7143-4320-A0E8-AD8CFB043859Q39176570-9E04DE19-FD56-4CB0-8017-81955343A035Q39205799-2858E3B2-D333-40D8-BE00-C143A17475C9Q40068221-3BAC626C-08D4-4C8D-A389-C3764E9803A6Q40113311-6D1890E5-5E82-4CD3-ABA7-1DDA960ACA14Q40336558-CB57FAAB-337A-4518-A301-58AAF16B082DQ40577440-B016E46C-89D8-41EB-A7F4-430EA112B308Q40593900-39343EDC-39B1-40DD-869C-F0A91D3AC90AQ42200313-AFDC71B2-9133-42DD-989B-2A02AC445D77Q42369758-C822921E-662F-4675-A284-D8BE27F80BE7Q42993860-2AA7DE0E-9A11-421B-B9EB-F66030B2A686Q43150730-9749EAE3-FC50-403D-BBA2-25F57045242EQ45857655-E67C7FD1-6265-45EE-A6DD-2C545792A68BQ47141979-09CA2DFF-7636-4AAA-9199-B0DCB959AA34Q47143961-D53908DC-1F4D-4AA9-BA97-6FC0B5F09984Q47148070-1AB6A939-4B44-4C26-A241-61D47081D569Q54210009-DBD54840-36B7-4ED8-A331-57D2917BCC26
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
NK cells require IL-28R for optimal in vivo activity
@ast
NK cells require IL-28R for optimal in vivo activity
@en
type
label
NK cells require IL-28R for optimal in vivo activity
@ast
NK cells require IL-28R for optimal in vivo activity
@en
prefLabel
NK cells require IL-28R for optimal in vivo activity
@ast
NK cells require IL-28R for optimal in vivo activity
@en
P2093
P2860
P50
P356
P1476
NK cells require IL-28R for optimal in vivo activity
@en
P2093
Arabella Young
Deepak Mittal
Kazuyoshi Takeda
Mariapia A Degli-Esposti
P2860
P304
P356
10.1073/PNAS.1424241112
P407
P50
P577
2015-04-21T00:00:00Z